Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Age-Related Blood Pressue Patterns in Lupus

Renée Bacher  |  June 15, 2020

Rheumatologists should not be falsely reassured by a normal mean blood pressure in lupus patients, according to a study from Johns Hopkins University that found age-related blood pressure patterns in systemic lupus erythematosus (SLE) differ from the general population and that increased diastolic blood pressure variability (BPV) is highly associated with cardiovascular events in SLE.1…

nukeaf / shutterstock.com

The History of Treating Lupus with Hydroxychloroquine

Ruth Jessen Hickman, MD  |  June 15, 2020

Given how unexpectedly front and center hydroxychloroquine has been in discussions about the treatment of COVID-19 this year, it makes sense to look at how it became so central to the treatment of a rheumatologic condition. In 1991, an article appeared in The New England Journal of Medicine that would alter the way rheumatologists approached…

Diagnosing & Treating Hemophagocytic Lymphohistiocytosis in Adults

Srujana Pachigolla, MD, & Adegbenga Bankole, MD  |  June 15, 2020

Primary hemophagocytic lymphohistiocytosis (HLH) is caused by genetic mutations and inherited syndromes; it therefore occurs in the pediatric age group. Secondary HLH, however, is more common in adults and is often triggered by other disease states, such as malignancies, chronic immuno­suppression, infections and autoimmune disease.1,2 Macrophage activation syndrome (MAS) is a subset of secondary HLH…

Medicalwriters/Science Source

Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology

Bryn Nelson, PhD  |  June 15, 2020

As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…

Advocacy in a COVID-19 America

Ellen M. Gravallese, MD  |  June 15, 2020

These are truly extraordinary times. The COVID-19 pandemic has affected the rheumatology community, both providers and patients, in many ways, and our advocacy efforts are now more important than ever to ensure policymakers hear us and help address the issues facing our community. As with so many things during this pandemic, we are reimagining advocacy…

We Make a Difference

Philip Seo, MD, MHS  |  June 15, 2020

“No!” she screamed. My niece just finished her first semester as a freshman at the University of St. Andrews in Scotland. If the institution sounds familiar to you, it may be because you remember a particularly famous graduate—William Windsor, who sometimes goes by his formal titles: Duke of Cambridge and heir to the British throne….

Akarat Phasura / shutterstock.com

The ACR Releases a New Gout Guideline

Susan Bernstein, with John FitzGerald, MD, PhD  |  June 15, 2020

In May, the ACR released a new treatment guideline for the management of gout for simultaneous publication in Arthritis & Rheumatology and Arthritis Care & Research.1 Based on evidence from more than 130 published studies, the guideline makes a total of 42 recommendations—of which 16 are strong: It has 27 recommendations for urate-lowering therapy (ULT)…

Collaborate, Innovate & Learn at ACR Convergence 2020: The ACR’s All-Virtual Annual Meeting

From the College  |  June 11, 2020

ACR Convergence 2020—the ACR’s annual meeting—will be presented online. Get ready for an innovative experience.

An Important Message from the ACR on the Death of George Floyd

From the College  |  June 11, 2020

The American College of Rheumatology is deeply troubled by the recent events surrounding the death of George Floyd. This tragedy is the latest in a long history of senseless killings of people of color. We recognize that racial inequality is an invisible undercurrent impacting the lives of many of our members and patients, and we…

Novel Cathepsin K Inhibitor Promising for OA

Lara C. Pullen, PhD  |  June 10, 2020

Research into the disease-modifying effects of the novel cathepsin K inhibitor MIV-711 suggests it may be effective as a knee OA treatment. In OA patients using the treatment, the study documented statistically significant reductions in bone and cartilage progression…

  • « Previous Page
  • 1
  • …
  • 197
  • 198
  • 199
  • 200
  • 201
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences